Compound: atenolol
SMILES: O=C(N)Cc1ccc(OCC(O)CNC(C)C)cc1
InChIKey: METKIMKYRPQLGS-UHFFFAOYSA-N
Synonyms: atenolol, 29122-68-7, Tenormin, Prenormine, Myocord, Duraatenolol, Betacard, Blokium, Corotenol, Normiten, Atehexal, Betablok, Cuxanorm, Juvental, Selobloc, Tenoblock, Antipressan, Atenblock, Farnormin, Internolol, Premorine, Vericordin, Anselol, Atcardil, Atecard, Atendol, Atereal, Evitocor, Hypoten, Ibinolo, Lotenal, Normalol, Prenolol, Stermin, Tenidon, Tenolol, Tenoprin, Tensimin, Vascoten, Wesipin, Alinor, Altol, Atenet, Ateni, Atenil, Aterol, Hipres, Noten, Oraday, Serten, Tredol, Uniloc, Xaten, Apo-Atenolol, Seles beta, Felo-Bits, Lo-ten, Atenolin, Atenomel, Blocotenol, Cardaxen, Cardiopress, Jenatenol, Panapres, Plenacor, Servitenol, Tenobloc, Aircrit, Betasyn, Ormidol, Prinorm, Unibloc, Loten, Atenol acis, Atenol Cophar, Atenol Fecofar, Atenol Heumann, Atenol Nordic, Atenol Quesada, Atenol Gador, Atenol Stada, Atenol-Mepha, Atenol-Wolff, Atenol Atid, Atenol ct, Atenol Genericon, Atenol Tika, Atenol Trom, Atenol von ct, Betatop Ge, Atenol-ratiopharm, Atenol AL, Atenol PB, Atenol GNR, Atenol MSD, Atenol NM Pharma, Atenololum, Scheinpharm Atenol, Atenol 1A pharma, ICI 66082, Novaten, ICI-66082, ICI 66,082, 2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide, 1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol, 2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide, 4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide, Vasaten, DTXSID2022628, 50VV3VW0TI, NSC-757832, Benzeneacetamide, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, C07AB03, 2-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide, CHEBI:2904, DTXCID202628, Acetamide, 2-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)-, 2-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide, 2-[p-[2-hydroxy-3-(isopropylamino)propoxy]phenyl]acetamide, atenololo, Atenamin, Totamol, 2-(4-(2-hydroxy-3-(propan-2-ylamino)propoxy)phenyl)acetamide, Kentol, 2-(4-(2-hydroxy-3-((propan-2-yl)amino)propoxy)phenyl)acetamide, Tenormin l.s., Tenormin 25, ICI66082, Atenix-25, Atenix-50, Atenix-100, RefChem:5571, Atenolol 29300-411, C07AB11, 2-(4-((2RS)-2-Hydroxy-3-((1-methylethyl)amino)propyloxy)phenyl)acetamide, 249-451-7, Tenormine, (RS)-Atenolol, 2-(4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide, Tenormine [French], 2-[4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl]acetamide, (r,s)-atenolol, Atenololum [INN-Latin], MFCD00057645, Tenormin (TN), 60966-51-0, CHEMBL24, duratenol, (R)-Atenolol-d7, MLS000069622, s4817, SMR000036768, Atenol, (+/-)-2-[4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl]acetamide, Teno-basan, (+/-)-Atenolol, 2-[4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl]acetamide, Neatenol, Tensotin, Atcard, dl-Atenolol, (+/-)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide, CCRIS 4196, HSDB 6526, SR-01000000159, 1309283-25-7, EINECS 249-451-7, EINECS 262-544-7, UNII-50VV3VW0TI, BRN 2739235, 2-(4-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl)acetamide, Artrenolol, 2-(4-(2-Hydroxy-3-(Isopropylamino)propoxy)phenyl)ethanamide, 2-(4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl)acetamid, 2-(4-{2-hydroxy-3-[(methylethyl)amino]propoxy}phenyl)acetamide, Prenormin;, Tenoblock;, Tenoretic;, Cuxanorm;, Selobloc;, Tenormin;, Myocord;, Totamol;, Atenix;, Atenol;, Atenolol RS, Atenolol CRS, Atenolol [USAN:BAN:INN:JAN], (y)-Atenolol, Atenalol (RS), (RS)-ateno lol, (?)-Atenolol, Atenolol (Standard), Atenolol [USAN:USP:INN:BAN:JAN], (A+/-)-Atenolol, Tenoretic (Salt/Mix), Atenolol (JAN/USP), Spectrum_001364, ATENOLOL [HSDB], ATENOLOL [USAN], ATENOLOL [INN], ATENOLOL [JAN], ATENOLOL [MI], ATENOLOL [VANDF], Opera_ID_1283, Spectrum2_001411, Spectrum3_001448, Spectrum4_000435, Spectrum5_001509, GlyTouCan:G93057SA, ATENOLOL [MART.], Atenolol Impurity Standard, ATENOLOL [USP-RS], ATENOLOL [WHO-DD], ATENOLOL [WHO-IP], A 7655, SCHEMBL4362, Lopac0_000121, Oprea1_448775, BSPBio_002915, GTPL548, KBioGR_000790, KBioSS_001844, Atenolol - Bio-X trade mark, MLS001066372, MLS001074163, MLS001304038, orb422215, DivK1c_000057, SPECTRUM1501127, Atenolol (JP18/USP/INN), SPBio_001482, ATENOLOL [ORANGE BOOK], orb1089783, ATENOLOL [EP MONOGRAPH], ATENOLOL [USP IMPURITY], ATENOLOL [USP MONOGRAPH], BDBM25753, HMS500C19, KBio1_000057, KBio2_001844, KBio2_004412, KBio2_006980, KBio3_002415, METKIMKYRPQLGS-UHFFFAOYSA-, Atenolol, 1mg/ml in Acetonitrile, ATENOLOLUM [WHO-IP LATIN], NINDS_000057, 2-{4-[2-Hydroxy-3-(isopropylamino)propoxy]-phenyl}acetamide, HMS1569L13, HMS1921H09, HMS2090I19, HMS2092D19, HMS2233E06, HMS3259K08, HMS3260I04, HMS3266K13, HMS3369B14, HMS3369D20, HMS3369P20, HMS3411G21, HMS3675G21, HMS3886G03, HMS5083P08, Pharmakon1600-01501127, ( inverted question mark)-Atenolol, TENORETIC COMPONENT ATENOLOL, Atenolol for system suitability CRS, G93057SA, JCC28325, MSK10056, Atenolol 1.0 mg/ml in Acetonitrile, Atenolol, >=98% (TLC), powder, Tox21_302426, Tox21_500121, 2-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide, BBL009276, CCG-39010, EBC-03835, GEO-03413, HY-17498R, NSC757832, SBB056998, STK528649, AKOS005111050, AC-8245, Atenolol, analytical reference material, DB00335, FH18009, KS-5341, LP00121, NC00548, NSC 757832, SDCCGSBI-0050109.P004, IDI1_000057, MRF-0000571, NCGC00015007-06, NCGC00015007-07, NCGC00015007-08, NCGC00015007-09, NCGC00015007-10, NCGC00015007-11, NCGC00015007-13, NCGC00015007-24, NCGC00024566-03, NCGC00024566-04, NCGC00024566-05, NCGC00024566-06, NCGC00024566-07, NCGC00255122-01, NCGC00260806-01, BA166036, DA-61290, HY-17498, ST024754, SBI-0050109.P003, CAS-29122-68-7, DB-072177, DB-079552, DB-214565, A1414, EU-0100121, NS00010385, BIM-0050109.0001, D00235, EN300-119532, O10469, AB00052208-13, AB00052208-15, AB00052208_16, L000116, Q411325, SR-01000000159-2, SR-01000000159-4, SR-01000000159-5, SR-01000000159-8, BRD-A20239487-001-02-5, BRD-A20239487-001-15-7, BRD-A20239487-001-24-9, BRD-A20239487-001-25-6, Atenolol, European Pharmacopoeia (EP) Reference Standard, Z1521553991, 4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxyl]benzeneacetamide, Atenolol, United States Pharmacopeia (USP) Reference Standard, 2-(P-(HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)PHENYL)ACETAMIDE, 2-(4-{[(2S)-2-hydroxy-3-(propan-2-ylamino)propyl]oxy}phenyl)acetamide, 2-[4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]acetamide, Atenolol, Pharmaceutical Secondary Standard; Certified Reference Material, 2-(P-(2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)PHENYL)ACETAMIDE (RACEMATE), 2-[4-({(2R)-2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide, 106020-65-9, InChI=1/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)
Theoretical properties:
molecular_formula: C14H22N2O3
molecular_weight: 266.34 g/mol
exact_mass: 266.16304257 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 3
hydrogen_bond_acceptor_count: 4
rotatable_bond_count: 8
heavy_atom_count: 19
topological_polar_surface_area: 84.6 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: White, crystalline powder
color: White, crystalline powder
melting_point: 158-160
Descriptions:
pubchem: Atenolol can cause developmental toxicity according to state or federal government labeling requirements.
chebi: An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an <em>N</em>-isopropyl substituent.
chembl: ATENOLOL is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Atenolol is a beta blocker medication primarily used to treat high blood pressure and heart-associated chest pain. Although used to treat high blood pressure, it does not seem to improve mortality in those with the condition. Other uses include the prevention of migraines and treatment of certain irregular heart beats. It is taken orally (by mouth) or by intravenous injection (injection into a vein). It can also be used with other blood pressure medications.
Common side effects include feeling tired, heart failure, dizziness, depression, and shortness of breath. Other serious side effects include bronchial spasm. Use is not recommended during pregnancy and alternative drugs are preferred when breastfeeding. It works by blocking β1-adrenergic receptors in the heart, thus decreasing heart rate, force of heart beats, and blood pressure.
Atenolol was patented in 1969 and approved for medical use in 1975. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the 75th most commonly prescribed medication in the United States, with more than 9 million prescriptions.